Abstract
Systemic mycoses are important opportunistic infections in immunocompromised patients. Candida, Aspergillus, and Mucoraceae are the most common causes of serious fungal infection in granulocytopenic patients, while Cryptococcus neoformans, Histoplasma capsulatum, and Coccidioides immitis are important pathogens in patients with impaired cellular immunity. Infections with less virulent fungi, such as Trichosporon, Fusarium, Alternaria, Pseudallescheria, dematiaceous fungi, and others, are being recognized more frequently.
Keywords
- Acute Leukemia
- Invasive Aspergillosis
- Graft Versus Host Disease
- Renal Transplant Patient
- Cryptococcal Meningitis
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Khardori N: Host—parasite interaction in fungal infections. Eur J Clin Microbiol Infect Dis 8: 331–351, 1989.
DeGregorio MW, Lee WMF, Linker CA, et al: Fungal infections in patients with acute leukemia. Am J Med 73: 543–548, 1982.
Pizzo PA, Ribichaud KJ, Gill FA, et al: Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med 72: 101–111, 1982.
Meyers JD: Fungal infection in bone marrow transplant patients. Semin Oncol 3: 10–13, 1990.
Tollemar J, Ringden O, Bostrom L, et al: Variables predicting deep fungal infections in bone marrow transplant recipients. Bone Marrow Transplant 4: 635–641, 1989.
Pirsch JD, Maki DG: Infectious complications in adults with bone marrow transplantation and T-cell depletion of donor marrow. Ann Intern Med 104: 619–631, 1986.
Benhamou E, Hartmann O, Nogues C, et al: Does ketoconazole prevent fungal infection in children treated with high dose chemotherapy and bone marrow transplantation? Results of a randomized placebo-controlled trial. Bone Marrow Transplant 7: 127–131, 1991.
Dekker AW, Rozenberg-Arska M, Sixma JJ, et al: Prevention of infection by trimethoprim-sulfamethoxazole plus amphotericin B in patients with acute nonlymphocytic leukemia. Ann Intern Med 95: 555–559, 1981.
Tricot G, Joosten E, Boogaerts MA, et al: Ketoconazole vs. itraconazole for antifungal prophylaxis in patients with severe granulocytopenia: Preliminary results of two nonrandomized studies. Rev Infect Dis 9(S1): S94–S99, 1987.
Wiley JM, Smith N, Leventhal BG, et al: Invasive fungal disease in pediatric acute leukemia patients with fever and neutropenia during induction chemotherapy: A multivariate analysis of risk factors. J Clin Oncol 8: 280–286, 1990.
Karp JE, Merz WG, Charache P: Response to empiric amphotericin B during antileukemic therapy—induced granulocytopenia. Rev Infect Dis 13: 592–599, 1991.
Wingard JR, Merz WG, Rinaldi MG, et al: Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med 325: 1274–1277, 1991.
Horn R, Wong B, Kiehn TE, et al: Fungemia in a cancer hospital: Changing frequency, earlier onset, and results of therapy. Rev Infect Dis 7: 646–655, 1985.
Maksymiuk AW, Thongprasert S, Hopfer R, et al: Systemic candidiasis in cancer patients. Am J Med 77: 20–27, 1984.
Pizzo PA, Walsh TJ: Fungal infection in the pediatric cancer patient. Semin Oncol 17: 6–9, 1990.
Nielsen H, Stenderup J, Bruun B: Fungemia in a university hospital 1984-1988. Scand J Infect Dis 23: 275–282, 1991.
Walsh TJ, Lee J, Lecciones J, et al: Empiric therapy with amphotericin B in febrile granulocytopenic patients. Rev Infect Dis 13: 496–503, 1991.
Burch PA, Karp JE, Merz WG, et al: Favorable outcome of invasive aspergillosis in patients with acute leukemia. J Clin Oncol 5: 1985–1993, 1987.
Pannuti CS, Gingrich RD, Pfaller MA, et al: Nosocomial pneumonia in adult patients undergoing bone marrow transplantation: A 9-year study. J Clin Oncol 9: 77–84, 1991.
Murphy JF, McDonald FD, Dawson M, et al: Factors affecting the frequency of infection in renal transplant recipients. Arch Intern Med 136: 670–677, 1976.
Scroggs MW, Wolfe JA, Bollinger RR, et al: Causes of death in renal transplant recipients. Arch Pathol Lab Med 111: 983–987, 1987.
Peterson PK, Balfour HH Jr, Fryd DS, et al: Fever in renal transplant recipients: Causes, prognostic significance and changing patterns at the University of Minnesota Hospital. Am J Med 71: 345–351, 1981.
Bach MC, Adler JL, Breman J, et al: Influence of rejection therapy on fungal and nocardia infections in renal-transplant recipients. Lancet 1: 180–184, 1973.
Fox BC, Sollinger HW, Beizer FO, et al: A prospective, randomized, double-blind study of trimethoprim-sulfamethoxazole for prophylaxis of infection in renal transplantation: Clinical efficacy, absorption of trimethoprim—sulfamethoxazole, effects on the microflora, and the cost-benefit of prophylaxis. Am J Med 89: 255–274, 1990.
Wiesner RH, Hermans PE, Rakela J, et al: Selective bowel decontamination to decrease gram-negative aerobic bacterial and Candida colonization and prevent infection after orthotopic liver transplantation. Transplantation 45: 570–574, 1988.
Castaldo P, Stratta RJ, Wood RP, et al: Clinical spectrum of fungal infections after orthotopic liver transplant. Arch Surg 126: 149–156, 1991.
Kusne S, Dumer JS, Singh N, et al: Infections after liver transplantation: An analysis of 101 consecutive cases. Medicine (Baltimore) 67: 132–143, 1988.
Colonna JO II, Winston DJ, Brill JE, et al: Infectious complications in liver transplantation. Arch Surg 123: 360–364, 1988.
Rossi G, Tortorano AM, Viviani MA, et al: Aspergillus fumigatus infection in liver transplant patients. Transplant Proc 21: 2268–2270, 1989.
Wajszczuk CP, Dummer JS, Ho M, et al: Fungal infections in liver transplant recipients. Transplantation 40: 347–353, 1985.
Ascher NL, Stock PG, Bumgardner GL, et al: Infection and rejection of primary hepatic transplant in 93 consecutive patients treated with triple immunosuppressive therapy. Surg Gynecol Obstetr 167: 474–484, 1988.
Schröter GPJ, Hoelscher M, Putman CW, et al: Fungus infection after liver transplantation. Ann Surg 186: 115–122, 1977.
Paya CV, Hermans PE, Washington JA II, et al: Incidence, distribution, and outcome of episodes of infection in 100 orthotopic liver transplantations. Mayo Clin Proc 64: 555–564, 1989.
Mora NP, Cofer JB, Solomon H, et al: Analysis of severe infections after 180 consecutive liver transplants: The impact of amphotericin B prophylaxis for reducing the incidence and severity of fungal infections. Transplant Proc 23: 1528–1530, 1991.
Boon AP, O’Brien D, Adams DH: 10 Year review of invasive aspergillosis detected at necropsy. J Clin Pathol 44: 452–454, 1991.
Hofflin JM, Potasman I, Baldwin JC, et al: Infectious complications in heart transplant recipients receiving cyclosporine and corticosteroids. Ann Intern Med 106: 209–216, 1987.
Imam N, Carpenter CCJ, Mayer ICH, et al: Hierarchical pattern of mucosal Candida infections in HIV-seropositive women. Am J Med 89: 142–146, 1990.
Syrjanen S, Valle SL, Antonen J, et al: Oral candidial infection as a sign of HIV infection in homosexual men. Oral Surg Oral Med Oral Pathol 65: 36–40, 1988.
Clark RA, Greer D, Atkinson W, et al: Spectrum of Cryptococcus neoformans infection in 68 patients infected with human immunodeficiency virus. Rev Infect Dis 12: 768–776, 1990.
Zuger Z, Louie E, Holzman RS, et al: Cryptococcal disease in patients with the acquired immunodeficiency syndrome: Diagnostic features and outcome of treatment. Ann Intern Med 104: 234–240, 1986.
Wheat LJ, Connolly-Stringfield PA, Baker RL, et al: Disseminated histoplasmosis in the acquired immune deficiency syndrome: Clinical findings, diagnosis and treatment, and review of the literature. Medicine (Baltimore) 69: 361–374, 1990.
Fish DG, Ampel NM, Galgiani JN, et al: Coccidioidomycosis during human immunodeficiency virus infection: A review of 72 patients. Medicine (Baltimore) 69: 384–391, 1990.
Denning DW, Follansbee SE, Scolaro M, et al: Pulmonary aspergillosis in the acquired immunodeficiency syndrome. New Engl J Med 324: 654–662, 1991.
Bergmann OJ: Alterations in oral microflora and pathogenesis of acute oral infections during remission-induction therapy in patients with acute myeloid leukaemia. Scand J Infect Dis 23: 355–366, 1991.
Powderly WG, Kobayashi GS, Herzig GP, et al: Amphotericin B—resistant yeast infection in severely immunocompromised patients. Am J Med 4: 826–832, 1988.
Bodey GP: Fungal infection and fever of unknown origin in neutropenic patients. Am J Med 80: 112–119, 1986.
Meunier-Carpentier F, Kiehn TE, Armstrong D: Fungemia in the immunocompromised host: Changing patterns, antigenemia, high mortality. Am J Med 71: 363–370, 1981.
Goodrich JM, Reed EC, Mori M, et al: Clinical features and analysis of risk factors for invasive candidal infection after marrow transplantation. J Infect Dis 164: 731–740, 1991.
Verfaillie C, Weisdorf D, Haake R, et al: Candida infections in bone marrow transplant recipients. Bone Marrow Transplant 8: 177–184, 1991.
Richet HM, Andremont A, Tancrede C, et al: Risk for candidemia in patients with acute lymphocytic leukemia. Rev Infect Dis 13: 211–215, 1991.
Komshian SV, Uwaydah, Sobel JD, et al: Fungemia caused by Candida species and Torulopis glabrata in the hospitalized patient: Frequency, characteristics, and evaluation of factors influencing outcome. Rev Infect Dis 11: 379–390, 1989.
Meunier F: Candidiasis. Eur J Clin Microbiol Infect Dis 8: 438–447, 1989.
Talbot GH, Provencher M, Cassileth PA: Persistent fever after recovery from granulocytopenia in acute leukemia. Arch Intern Med 148: 129–135, 1988.
Marina NM, Flynn PM, Rivera GK, et al: Candida tropicalis and Candida albicans fungemia in children with leukemia. Cancer 68: 594–599, 1991.
Lewis JH, Patel HR, Zimmerman HJ: The spectrum of hepatic candidiasis. Hepatology 2: 479–487, 1982.
Silverman RA, Rhodes AR, Dennehy PH: Disseminated intravascular coagulation and purpura fulminans in a patient with Candida sepsis: Biopsy of purpura fulminans as an aid to diagnosis of systemic Candida infection. Am J Med 80: 679–684, 1986.
Thaler M, Pastakia B, Shawker TH, et al: Hepatic candidiasis in cancer patients: The evolving picture of the syndrome. Ann Intern Med 108: 88–100, 1988.
Escuro RS, Jacobs M, Gerson SL, et al: Prospective evaluation of a Candida antigen detection test for invasive candidiasis in immunocompromised adult patients with cancer. Am J Med 87: 621–627, 1989.
Walsh TJ, Hathorn JW, Sobel JD, et al: Detection of circulating Candida enolase by immunoassay in patients with cancer and invasive candidiasis. New Engl J Med 324: 1026–1031, 1991.
Sugar AM: Empiric treatment of fungal infections in the neutropenic host. Arch Intern Med 150: 2258–2264, 1990.
European Organization for Research on Treatment of Cancer International Antimicrobial Therapy Cooperative Group: Empiric antifungal therapy in febrile granulocytopenic patients. Am J Med 86: 668–672, 1989.
Perfect JR, Klotman ME, Gilbert CC, et al: Prophylactic intravenous amphotericin B (AMB) in neutropenic autologous bone marrow transplant recipients (BMT). Abstract 1246. Interscience Conference on Antimicrobial Agents and Chemotherapy, 1991.
Fainstein V, Bodey GP, Elting L, et al: Amphotericin B or ketoconazole therapy of fungal infections in neutropenic cancer patients. Antimicrob Agents Chemother 31: 11–15, 1987.
Anaissie E, Bodey GP, Kantarjian H, et al: Fluconazole therapy for chronic disseminated candidiasis in patients with leukemia and prior amphotericin B therapy. Am J Med 91: 142–150, 1991.
Kauffman CA, Bradley SF, Ross SC, et al: Hepatosplenic candidiasis: Successful treatment with fluconazole. Am J Med 91: 137–141, 1991.
Fox R, Neal KR, Leen CLS, et al: Fluconazole resistant Candida in AIDS. J Infect 22: 201–212, 1991.
McIlroy MA: Failure of fluconazole to suppress fungemia in a patient with fever, neutropenia, and typhlitis. J Infect Dis 163: 420–421, 1991.
Guinet R, Marlier H: Sensibilité comparée des levures aux ketoconazole, itraconazole et fluconazole en micromethode standardisée en milieu liquide. Pathol Biol 38: 575–578, 1990.
Van’t Wout JW, Novakova I, Verhagen CAH, et al: The efficacy of itraconazole against systemic fungal infections in neutropenic patients: A randomized comparative study with amphotericin B. J Infect 22: 45–52, 1991.
Lopez-Berestein G, Bodey GP, Fainstein V, et al: Treatment of systemic fungal infections with liposomal amphotericin B. Arch Intern Med 149: 2533–2536, 1989.
Wingard JR, Merz WG, Saral R: Candida tropicalis: A major pathogen in immunocompromised patients. Ann Intern Med 91: 539–543, 1979.
Eiff MV, Fahrenkamp A, Roos N, et al: Hepatosplenic candidosis—a late manifestation of Candida septicemia. Mycoses 3: 283–290, 1990.
Goodman J, Buell D, Gilbert G (for the Seventeen Member Marrow Transplant Study Group, University of Minnesota, Minneapolis, and Pfizer Central Research, Groton, CT): Fluconazole prevents fungal infections in bone marrow transplantation (BMT): Results of a placebo-controlled, double-blind, randomized, multicenter trial. Abstract PS3.114. International Society for Human and Animal Mycology, 1991.
Bodey GP, Samonis G, Rolston K: Prophylaxis of candidiasis in cancer patients. Semin Oncol 17(S6): 24–28, 1990.
Arska-Rozenberg M, Dekker AW, Branger J, et al: A randomized study to compare oral fluconazole to amphotericin B in the prevention of fungal infections in patients with acute leukaemia. J Antimicrob Chemother 27: 369–376, 1991.
Hansen RM, Reinerio N, Sohnle PG, et al: Ketoconazole in the prevention of candidiasis in patients with cancer. Arch Intern Med 147: 710–712, 1987.
Benhamou E, Hartmann O, Nogues C, et al: Does ketoconazole prevent fungal infection in children treated with high dose chemotherapy and bone marrow transplantation? Results of a randomized placebo-controlled trial. Bone Marrow Transplant 7: 127–131, 1991.
Meunier F: Prevention of mycoses in immunocompromised patients. Rev Infect Dis 9: 408–416, 1987.
Milliken ST, Powles RL: Antifungal prophylaxis in bone marrow transplantation. Rev Infect Dis 12(S3): S374–S379, 1990.
Blinker H: Prevention of mycosis in granulocytopenic patients with prophylactic ketoconazole treatment. Mykosen 26: 242–247, 1983.
Shepp DH, Klosterman A, Siegel MS, et al: Comparative trial of ketoconazole and nystatin for prevention of fungal infection in neutropenic patients treated in a protective environment. J Infect Dis 152: 1257–1262, 1985.
Estey E, Maksymiuk A, Smith T, et al: Infection prophylaxis in acute leukemia. Arch Intern Med 144: 1561–1568, 1984.
Cuttner J, Troy KM, Funaro L, et al: Clotrimazole treatment for prevention of oral candidiasis in patients with acute leukemia undergoing chemotherapy: Results of a double-blind study. Am J Med 81: 771–774, 1986.
Owens NJ, Nightingale CH, Schweizer RT, et al: Prophylaxis of oral candidiasis with clotrimazole troches. Arch Intern Med 144: 290–293, 1984.
Wingard JR, Vaughan WP, Braine HG, et al: Prevention of fungal sepsis in patients with prolonged neutropenia: A randomized, double-blind, placebo-controlled trial of intravenous miconazole. Am J Med 83: 1103–1110, 1987.
Bodey GP, Rosenbaum B, Valdivieso M, et al: Effect of systemic antimicrobial prophylaxis on microbial flora. Antimicrob Agents Chemother 21: 367–372, 1982.
Eddinli EZ, O’Sullivan DD, Wasser LP, et al: Oral amphotericin for candidiasis in patients with hematologic neoplasms. JAMA 242: 258–260, 1979.
Perfect JR, Klotman ME, Gilbert CC, et al: Prophylactic intravenous amphotericin B in neutropenic autologous bone marrow transplant recipients. Abstract 1245. 31st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, September 29-October 2, 1991.
Ferretti GA, Ash RC, Brown AT, et al: Control of oral mucositis and candidiasis in marrow transplantation: A prospective, double-blind trial of chlorhexidine digluconate oral rinse. Bone Marrow Transplant 3: 483–493, 1983.
Doebbeling BN, Hollis RJ, Isenberg HD, et al: Restriction fragment analysis of a Candida tropicalis outbreak sternal wound infection. J Clin Microbiol 29: 1268–1270, 1991.
Bodey GP, Johnston D: Microbiological evaluation of protected environments during patient occupancy. Appl Microbiol 22: 828–836, 1971.
Rinaldi MG: Invasive aspergillosis. Rev Infect Dis 5: 1061–1077, 1983.
Bodey GP, Vartivarian S: Aspergillosis. Eur J Clin Microbiol Infect Dis 8: 413–437, 1989.
Aisner J, Murillo J, Schimpff SC, et al: Invasive aspergillosis in acute leukemia: Correlation with nose cultures and antibiotic use. Ann Intern Med 90: 4–9, 1979.
Gerson SL, Talbot GH, Hurwitz S, et al: Prolonged granulocytopenia: The major risk factor for invasive pulmonary aspergillosis in patients with acute leukemia. Ann Intern Med 100: 345–351, 1984.
Sherertz RJ, Belani A, Kramer BS, et al: Impact of air filtration on nosocomial Aspergillus infections: Unique risk of bone marrow transplant recipients. Am J Med 83: 709–718, 1987.
Robertson MJ, Larson RA: Recurrent fungal pneumonias in patients with acute nonlymphocytic leukemia undergoing multiple courses of intensive chemotherapy. Am J Med 84: 233–239, 1988.
Karp E, Burch PA, Merz WG: An approach to intensive antileukemia therapy in patients with previous invasive aspergillosis. Am J Med 85: 203–206, 1988.
Armstrong D: Problems in management of opportunistic fungal diseases. Rev Infect Dis 11(S7): S1591–S1599, 1989.
Hamadeh R, Ardehali A, Locksley RM, et al: Fatal aspergillosis associated with smoking contaminated marijuana, in a marrow transplant recipient. Chest 94: 432–433, 1984.
Allo MD, Miller J, Townsend T, et al: Primary cutaneous aspergillosis associated with Hickman intravenous catheters. New Engl J Med 317: 1105–1108, 1987.
Meyer RD, Young LS, Armstrong D, et al: Aspergillosis complicating neoplastic disease. Am J Med 54: 6–15, 1973.
Denning DW, Stevens DA: Antifungal and surgical treatment of invasive aspergillosis: Review of 2, 121 published cases. Rev Infect Dis 12: 1147–1201, 1990.
Clark A, Skeleton J, Fraser RS: Fungal tracheobronchitis: Report of 9 cases and review of the literature. Medicine (Baltimore) 70: 1–14, 1991.
Talbot GH, Huang A, Provencher M: Invasive Aspergillus rhinosinusitis in patients with acute leukemia. Rev Infect Dis 13: 219–232, 1991.
Reiss P, Hadderingh R, Schot LJ, et al: Invasive external otitis caused by Aspergillus fumigatus in two patients with AIDS. AIDS 5: 605–606, 1991.
Boon AP, Adams DH, Buckels J, et al: Cerebral aspergillosis in liver transplantation. J Clin Pathol 43: 114–118, 1990.
Woods GL, Wood RP, Shaw, BW Jr: Aspergillus endocarditis in patients without prior cardiovascular surgery: Report of a case in liver transplant recipient and review. Rev Infect Dis 11: 263–272, 1989.
Fisher D, Armstrong D, Yu B, et al: Invasive aspergillosis: Progress in early diagnosis and treatment. Am J Med 71: 571–577, 1981.
Rogers TR, Kaynes KA, Barnes RA: Value of antigen detection in predicting invasive pulmonary aspergillosis. Lancet 336: 1210–1213, 1990.
Albelda SM, Talbot GH, Gerson SL, et al: Role of fiberoptic bronchoscopy in the diagnosis of invasive pulmonary aspergillosis in patients with acute leukemia. Am J Med 76: 1027–1034, 1984.
Treger TR, Visscher DW, Bartlett MS, et al: Diagnosis of pulmonary infection caused by Aspergillus: Usefulness of respiratory cultures. J Infect Dis 152: 572–576, 1985.
Hiddemann W, Essink ME, Fegeler W, et al: Clinical trials: Antifungal treatment by amphotericin B and 5-flucytosine delays the recovery of normal hematopoietic cells after intensive cytostatic therapy for acute myeloid leukemia. Cancer 68: 9–14, 1991.
Denning DW, Tucker RM, Hanson LH, et al: Treatment of invasive aspergillosis with itraconazole. Am J Med 86: 791–800, 1989.
Viviani MA, Tortorano AM, Pagano A, et al: European experience with itraconazole in systemic mycoses. J Am Acad Dermatol 23: 587–593, 1990.
Dupont B: Itraconazole therapy in aspergillosis: Study in 49 patients. J Am Acad Dermatol 23: 607–614, 1990.
Voilier AF, Peterson DE, DeJongh CA, et al: Aspergillus sinusitis in cancer patients. Cancer 58: 366–371, 1986.
Schattenberg A, DeVries F, DeWitte T, et al: Allogenic bone marrow transplantation after partial lobectomy for aspergillosis of the lung. Bone Marrow Transplant 3: 509–512, 1988.
Goering P, Berlinger NT, Weisdorf DJ: Aggressive combined modality treatment of progressive sinonasal fungal infections in immunocompromised patients. Am J Med 85: 619–623, 1988.
Opal SM, Asp AA, Canady PB Jr, et al: Efficacy of infection control measure during a nosocomial outbreak of disseminated aspergillosis associated with hospital construction. J Infect Dis 153: 634–637, 1986.
Conneally E, Cafferkey MT, Daly PA, et al: Nebulized amphotericin B as prophylaxis against invasive aspergillosis in granulocytopenic patients. Bone Marrow Transplant 5: 403–406, 1990.
Meunier-Carpentier F: Chemoprophylaxis of fungal infections. Am J Med 76: 652–656, 1984.
Jeffery GM, Beard MEJ, Ikram RB, et al: Intranasal amphotericin B reduces the frequency of invasive aspergillosis in neutropenic patients. Am J Med 90: 685–692, 1991.
Jorgensen CJ, Dreyfus F, Vaixeler J, et al: Failure of amphotericin B spray to prevent aspergillosis in granulocytopenic patients. Nouv Rev Fr Hematol 31: 327–328, 1989.
Ingram CW, Sennesh J, Cooper JN, et al: Disseminated zygomycosis: Report of four cases and review. Rev Infect Dis 11: 741–754, 1989.
Meyer RD, Rosen P, Armstrong D: Phycomycosis complicating leukemia and lymphoma. Ann Intern Med 77: 871–879, 1972.
Morduchowicz G, Shmueli D, Shapira Z, et al: Rhinocerebral mucormycosis in renal transplant recipients: Report of three cases and review of the literature. Rev Infect Dis 8: 441–446, 1986.
Blitzer A, Lawson W, Meyers BR, et al: Patient survival factors in paranasal sinus mucormycosis. Laryngoscope 90: 635–648, 1980.
Ferguson BJ, Mitchell TG, Moon R, et al: Adjunctive hyperbaric oxygen for treatment of rhinocerebral mucormycosis. Rev Infect Dis 10: 551–559, 1988.
Hsu J, Clayman JA, Geha AS: Survival of a recipient of renal transplantation after pulmonary phycomycosis. Ann Thorac Surg 47: 617–619, 1989.
Lehrer RI, Howard DH, Sypherd PS, et al: Mucormycosis. Ann Intern Med 93: 93–108, 1980.
Dismukes WE: Cryptococcal meningitis in patients with AIDS. J Infect Dis 157: 624–628, 1988.
Chuck SL, Sande MA: Infections with Cryptococcus neoformans in the acquired immunodeficiency syndrome. New Engl J Med 321: 794–799, 1989.
Eng RHK, Bishburg E, Smith SM, et al: Cryptococcal infections in patients with acquired immune deficiency syndrome. Am J Med 81: 19–23, 1986.
Kovax JA, Kovacs AA, Polis M, et al: Cryptococcosis in the acquired immunodeficiency syndrome. Ann Intern Med 103: 533–538, 1985.
Watson AJ, Whelton A, Russell RP: Cure of cryptococcemia and preservation of graft function in a renal transplant recipient. Arch Intern Med 144: 1877–1878, 1984.
Kong NCT, Shaariah W, Morad Z, et al: Cryptococcosis in a renal unit. Aust NZ J Med 20: 645–649, 1990.
Ramsey PG, Rubin RH, Tolkoff-Rubin NE, et al: The renal transplant patient with fever and pulmonary infiltrates: Etiology, clinical manifestations, and management. Medicine (Baltimore) 59: 206–222, 1980.
Britt RH, Enzmann DR, Remington JS: Intracranial infection in cardiac transplant recipients. Ann Neurol 9: 107–119, 1981.
Saral R: Candida and Aspergillus infections in immunocompromised patients: An overview. Rev Infect Dis 13: 487–492, 1991.
Perfect JR, Durack DT, Gallis HA: Cryptococcemia. Medicine (Baltimore) 62: 98–109, 1983.
Schröter GPJ, Temple DR, Husberg BS, et al: Cryptococcosis after renal transplantation: Report of ten cases. Surgery 79: 268–277, 1976.
Watson AJ, Russell RP, Cabreja RF, et al: Cure of cryptococcal infection during continued immunosuppressive therapy. Q J Med 55: 169–172, 1985.
Kerkering TM, Duma RJ, Shadomy S: The evolution of pulmonary cryptococcosis: Clinical implications from a study of 41 patients with and without compromising host factors. Ann Intern Med 94: 611–616, 1981.
Dismukes WE, Cloud G, Gallis HA, et al (National Institute of Allergy and Infectious Diseases Mycoses Study Group): Treatment of cryptococcal meningitis with combination amphotericin B and flucytosine for four as compared with six weeks. N Engl J Med 317: 334–341, 1987.
Chan K-H, Mann KS, Yue CP: Neurosurgical aspects of cerebral cryptococcosis. Neurosurgery 25: 44–48, 1989.
Hamilton JR, Noble A, Denning DW, et al: Performance of cryptococcus antigen latex agglutination kits on serum and cerebrospinal fluid specimens of AIDS patients before and after pronase treatment. J Clin Microbiol 29: 333–339, 1991.
Gade W, Hinnefeld SW, Babcock LS, et al: Comparison of the PREMIER cryptococcal antigen enzyme immunoassay and the latex agglutination assay for detection of cryptococcal antigens. J Clin Microbiol 29: 1616–1619, 1991.
Bennett JE, Dismukes WE, Duma RJ, et al: A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptococcal meningitis. N Engl J Med 301: 126–131, 1979.
Larsen RA, Leal MAE, Chan LS: Fluconazole compared with amphotericin B plus flucytosine for cryptococcal meningitis in AIDS. Ann Intern Med 113: 183–187, 1990.
Polsky B, Depman MR, Gold JWM, et al: Intraventricular therapy of cryptococcal meningitis via a subcutaneous reservoir. Am J Med 81: 24–28, 1986.
Saag MS, Powderly WG, Cloud GA, et al, and the NIAID Mycoses Study Group and the AIDS Clinical Trials Group: Treatment of acute AIDS-associated cryptococcal meningitis with amphotericin B or fluconazole: Results of a randomized clinical trial. New Engl J Med 326: 83–89, 1992.
Denning DW, Tucker RM, Hanson LH, et al: Itraconazole therapy for cryptococcal meningitis and cryptococcosis. Arch Intern Med 149: 2301–2308, 1989.
Bozzette SA, Larsen RA, Chiu J, et al (California Collaborative Treatment Group): A placebo-controlled trial of maintenance therapy with fluconazole after treatment of cryptococcal meningitis in the acquired immunodeficiency syndrome. New Engl J Med 324: 580–584, 1991.
Powderly WG, Saag MS, Cloud GA, et al, and the NIAID AIDS Clinical Trials Group and Mycoses Study Group: A randomized controlled trial of fluconazole versus amphotericin B as maintenance therapy for prevention of relapse of AIDS-associated cryptococcal meningitis. N Engl J Med 326: 793–798, 1992.
Iitaka K, McEnery PT, West CD: Successful renal transplantation after generalized cryptococcosis. J Pediatr 92: 422–423, 1978.
Mills SA, Seigier HF, Wolfe WG: The incidence and management of pulmonary mycosis in renal allograft patients. Ann Sur g 182: 617–626, 1975.
Sathapatayavongs B, Batteiger BE, Wheat LJ, et al: Clinical and laboratory features of disseminated histoplasmosis during two large urban outbreaks. Medicine (Baltimore) 62: 263–270, 1983.
Davies SF, Khan M, Sarosi GA: Disseminated histoplasmosis in immunologically suppressed patients. Am J Med 64: 94–100, 1978.
Kauffman CA, Israel KS, Smith JW, et al: Histoplasmosis in immunosuppressed patients. Am J Med 64: 923–932, 1978.
Wheat LJ, Smith EJ, Sathapatayavongs B, et al: Histoplasmosis in renal allograft recipients: Two large urban outbreaks. Arch Intern Med 143: 703–707, 1983.
Hughes WT: Hematogenous histoplasmosis in the immunocompromised child. J Pediatr 105: 569–575, 1984.
Hood AB, Inglis FG, Lowenstein L, et al: Histoplasmosis and thrombocytopenic purpura: Transmission by renal homotransplantation. Can Med Assoc J 93: 587–592, 1965.
Wheat LJ, Slama TG, Norton JA, et al: Risk factor for disseminated or fatal histoplasmosis: Analysis of a large urban outbreak. Ann Intern Med 96: 159–163, 1982.
Sridhar NR, Tchervenkov JI, Weiss MA, et al: Disseminated histoplasmosis in a renal transplant patient: Renal failure several years following transplantation. Am J Kidney Dis 17: 719–721, 1991.
McKinsey DS, Gupta MR, Riddler SA, et al: Long-term amphotericin B therapy for disseminated histoplasmosis in patients with the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 111: 655–659, 1989.
Wheat LJ, Köhler RB, Tewari RP: Diagnosis of disseminated histoplasmosis by detection of Histoplasma capsulatum antigen in serum and urine specimens. New Engl J Med 314: 83–88, 1986.
Wheat LJ, Connolly-Stringfield P, Blair R, et al: Effect of successful treatment with amphotericin B on Histoplasma capsulatum variety capsulatum polysaccharide antigen levels in patients with AIDS and histoplasmosis. Am J Med 92: 153–160, 1992.
Wheat LJ, Connolly-Stringfield P, Blair R, et al: Diagnosis of histoplasmosis relapse in patients with AIDS by Histoplasma capsulatum variety capsulatum antigen detection. Ann Intern Med 115: 936–941, 1991.
Dismukes WE: Treatment of blastomycosis and histoplasmosis with ketoconazole: Results of a prospective randomized clinical trial. Ann Intern Med 103: 861–872, 1985.
Slama TG: Treatment of disseminated and progressive cavitary histoplasmosis with ketoconazole. Am J Med 74(1D): 70–73, 1983.
Negroni R, Robles AM, Arechavala A, et al: Itraconazole in human histoplasmosis. Mycoses 32: 123–130, 1989.
Cohen IM, Galgiani JN, Potter D, et al: Coccidioidomycosis in renal replacement therapy. Arch Intern Med 142: 489–494, 1982.
Calhoun DL, Galgiani JN, Zukoski C, et al: Coccidioidomycosis in recent renal or cardiac transplant recipients. In Einstein HE, Catanzaro A (eds): Proceedings of the 4th International Conference on Coccidioidomycosis. National Foundation for Infectious Diseases, Washington DC, 1985, pp. 312–318.
Ampel NM, Ryan KJ, Carry PJ, et al: Fungemia due to Coccidioides immitis. Medicine (Baltimore) 65: 312–321, 1986.
Galgiani JN, Ampel NM: Coccidioidomycosis in human immunodeficiency virus-infected patients. J Infect Dis 162: 1165–1169, 1990.
Bronnimann DA, Adam RD, Galgiani JN, et al: Coccidioidomycosis in the acquired immunodeficiency syndrome. Ann Intern Med 106: 372–379, 1987.
Drutz DJ, Catanzaro A: Coccidioidomycosis. Part I. Am Rev RespirDis 117: 559–585, 1978.
Brewer JH, Parrott CL, Rimland D: Disseminated coccidioidomycosis in a heart transplant recipient. Sabouraudia 20: 261–265, 1982.
Deresinski SC, Stevens DA: Coccidioidomycosis in compromised hosts: Experience at Stanford University Hospital. Medicine (Baltimore) 54: 377–395, 1974.
Vartivarian SE, Coudron PE, Markowitz SM: Disseminated coccidioidomycosis: Unusual manifestations in a cardiac transplantation patient. Am J Med 83: 949–952, 1987.
Schröter GPJ, Bakshandeh K, Husberg BS, et al: Coccidioidomycosis and renal transplantation. Transplantation 23: 485–489, 1977.
MacDonald N, Steinhoff MC, Powell KR: Review of coccidioidomycosis in immunocompromised children. Am J Dis Child 135: 553–556, 1981.
Ampel NM, Wieden MA, Galgiani JN: Coccidioidomycosis: Clinical update. Rev Infect Dis 11: 897–911, 1989.
Drutz DJ, Catanzaro A: Coccidioidomycosis. Part II. Am Rev Respir Dis 117: 727–771, 1978.
Wack EE, Dugger KO, Galgiani JN: Enzyme-linked immunosorbent assay for antigens of Coccidioides immitis: Human sera interference corrected by acidification-heat extraction. J Lab Clin Med 111: 560–565, 1988.
Graybill JR, Stevens DA, Galgiani JN, et al: Itraconazole treatment of coccidioidomycosis. Am J Med 89: 282–290, 1990.
Labadie EL, Hamilton RH: Survival improvement in coccidioidal meningitis by high-dose intrathecal amphotericin B. Arch Intern Med 146: 2013–2018, 1986.
Galgiani JN, Stevens DA, Graybill JR, et al: Ketoconazole therapy of progressive coccidioidomycosis: Comparison of 400-and 800-mg doses and observations at higher doses. Am J Med 84: 603–610, 1988.
Robinson PA, Knirsch AK: Fluconazole for life-threatening fungal infections in patients who cannot be treated with conventional antifungal agents. Rev Infect Dis 12: S349–S363, 1990.
Tucker RM, Denning DW, Arathoon EG, et al: Itraconazole therapy for nonmeningeal coccidioidomycosis: Clinical and laboratory observations. J Am Acad Dermatol 23: 593–601, 1990.
Tucker RM, Haq Y, Denning DW, et al: Adverse events associated with itraconazole in 189 patients on chronic therapy. J Antimicrob Chemother 26: 561–566, 1990.
Diaz M, Puente R, de Hoyos LA, et al: Itraconazole in the treatment of coccidioidomycosis. Chest 100: 682–684, 1991.
Anaissie E, Bodey GP, Kantarjian H, et al: New spectrum of fungal infection in patients with cancer. Rev Infect Dis 11: 369–378, 1989.
Anaissie EJ, Bodey GP, Rinaldi MG: Emerging fungal pathogens. Eur J Clin Microbiol Infect Dis 8: 323–330, 1989.
Walsh TJ, Pizzo A: Treatment of systemic fungal infections: Recent progress and current problems. Eur J Clin Microbiol Infect Dis 7: 460–475, 1988.
Merz WG, Karp JE, Hoagland M, et al: Diagnosis and successful treatment of fusariosis in the compromised host. J Infect Dis 158: 1046–1055, 1988.
Patterson TF, Andriole VT, Zervos MJ, et al: The epidemiology of pseudallescheriasis complicating transplantation: Nosocomial and community-acquired infection. Mycoses 33: 297–302, 1990.
Sharkey PK, Graybill JR, Rinaldi MG, et al: Itraconazole treatment of phaeohyphomycosis. J Am Acad Dermatol 23: 577–586, 1990.
Lowenthal RM, Atkinson K, Challis DR, et al: Invasive Trichosporon cutaneum infection: An increasing problem in immunosuppressed patients. Bone Marrow Transplant 2: 321–327, 1987.
Gallis HA, Drew RH, Pickard WW: Amphotericin B: 30 Years of clinical experience. Rev Infect Dis 12: 308–329, 1990.
Stamm AM, Diasio RB, Dismukes WE, et al: Toxicity of amphotericin B plus flucytosine in 194 patients with cryptococcal meningitis. Am J Med 83: 236–242, 1987.
Fisher MA, Talbot GH, Maislin G, et al: Risk factors for amphotericin B-associated nephrotoxicity. Am J Med 87: 547–552, 1989.
Lin AC, Bernard EM, Chapman SW: Amphotericin B blunts erythropoietin response to anemia. J Infect Dis 161: 348–351, 1990.
Meeker TC, Siegel MS, Shiota FM, et al: Toxicity of amphotericin B, miconazole, and ketoconazole to human granulocyte progenitor cells in vitro. Antibiot Chemother 23: 169–171, 1983.
Kan VL, Bennett JE, Amantea MA, et al: Comparative safety, tolerance, and pharmacokinetics of amphotericin B lipid complex and amphotericin B desoxycholate in healthy male volunteers. J Infect Dis 164: 418–421, 1991.
Wiebe VJ, DeGregorio MW: Liposome encapsulated amphotericin B: Promising new treatment for disseminated fungal infections. Rev Infect Dis 10: 1097–1101, 1988.
Blum RA, D’Andrea DT, Florentino BM, et al: Increased gastric pH and the bioavailability of fluconazole and ketoconazole. Ann Intern Med 114: 755, 1991.
Piscitelli SC, Goss TF, Wilton JH, et al: Effects of ranitidine and sucralfate on ketoconazole bioavailability. Antimicrob Agents Chemother 35: 1765–1771, 1991.
Knight TE, Shikuma CY, Knight J: Ketoconazole-induced fulminant hepatitis necessitating liver transplantation. J Am Acad Dermatol 25: 398–400, 1991.
Englehard D, Stutman HR, Marks MI: Interaction of ketoconazole with rifampin and isoniazid. N Engl J Med 26: 1681–1683, 1984.
Doble N, Shaw R. Rowland-Hill C, et al: Pharmacokinetic study of the interaction between rifampicin and ketoconazole. J Antimicrob Chemother 21: 633–635, 1988.
Brass C, Galgiani JN, Blaschke TF, et al: Disposition of ketoconazole, an oral antifungal, in humans. Antimicrob Agents Chemother 21: 151–158, 1982.
First MR, Schroeder TJ, Alexander JW, et al: Cyclosporine dose reduction by ketoconazole administration in renal transplant recipients. Transplantation 51: 365–370, 1991.
Glynn AM, Slaughter RL, Brass C, et al: Effects of ketoconazole on methylprednisolone pharmacokinetics and cortisol secretion. Clin Pharmacol Ther 39: 654–659, 1986.
Kitchen VS, Savage M, Harris JRW: Candida albicans resistance in AIDS: Letter to the Editor. J Infect 22: 204–205, 1991.
Ikemoto H: A clinical study of fluconazole for the treatment of deep mycoses. Diagn Microbiol Infect Dis 12: 239S–247S, 1989.
Brammer KW, Farrow PR, Faulkner JK: Clinical pharmacology: Pharmacokinetics and tissue penetration of fluconazole in humans. Rev Infect Dis 12: S318–S326, 1990.
Apseloff G, Hilligoss DM, Gardner MJ, et al: Induction of fluconazole metabolism by rifampin: In vivo study in humans. J Clin Pharmacol 31: 358–361, 1991.
Blum RA, Wilton JH, Hilligoss DM, et al: Effect of fluconazole on the disposition of phenytoin. Clin Pharmacol Ther 49: 420–425, 1991.
Lazar JD, Wilner KD: Drug interactions with fluconazole. Rev Infect Dis 12: S327–S333, 1990.
Canafax DM, Graves NM, Hilligoss DM, et al: Increased cyclosporine levels as a result of simultaneous fluconazole and cyclosporine therapy in renal transplant recipients: A double-blind, randomized pharmacokinetic and safety study. Transplant Proc 23: 1041–1042, 1991.
Sugar AM, Saunders C: Oral fluconazole as suppressive therapy of disseminated cryptococcosis in patients with acquired immunodeficiency syndrome. Am J Med 85: 481–489, 1988.
Agarwal A, Sakhuja V, Chugh KS: Fluconazole-induced thrombocytopenia. Ann Intern Med 113: 899, 1990.
Gussenhoven MJE, Haak A, Peerboom-Wynia JDR: Stevens-Johnson syndrome after fluconazole. Lancet 338: 120, 1991.
Neuhaus G, Pavic N, Pletscher M: Anaphylactic reaction after oral fluconazole. Br Med J 287: 1673, 1984.
Grant SM, Clissold SP: Itraconazole: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses. Drugs 37: 310–344, 1989.
Blomley M, Teare EL, DeBelder A, et al: Itraconazole and antituberculosis drugs. Lancet 336: 1255, 1990.
Kramer MR, Marshall SE, Denning DW, et al: Cyclosporine and itraconazole interaction in heart and lung transplant recipients. Ann Intern Med 113: 327–329, 1990.
Tucker RM, Denning DW, Dupont B, et al: Itraconazole therapy for chronic coccidioidal meningitis. Ann Intern Med 112: 108–112, 1990.
Sharkey PK, Rinaldi MG, Dunn JF, et al: High-dose itraconazole in the treatment of severe mycoses. Antimicrob Agents Chemother 35: 707–713, 1991.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1994 Plenum Publishing Corporation
About this chapter
Cite this chapter
Wheat, L.J. (1994). Fungal Infections in the Immunocompromised Host. In: Rubin, R.H., Young, L.S. (eds) Clinical Approach to Infection in the Compromised Host. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-2490-8_8
Download citation
DOI: https://doi.org/10.1007/978-1-4615-2490-8_8
Publisher Name: Springer, Boston, MA
Print ISBN: 978-0-306-44617-7
Online ISBN: 978-1-4615-2490-8
eBook Packages: Springer Book Archive